Guardant Health

Guardant Health helps doctors find and track cancer using simple blood tests instead of invasive surgery. These tests look for tiny pieces of tumor DNA in a patient's bloodstream to help choose the best medicines. The company also builds data tools to help researchers develop new cancer treatments faster.

The Product Portfolio

• Therapy Selection: Blood-based tests like Guardant360 CDx and Guardant360 Tissue that identify specific mutations in advanced cancers to guide treatment choices.
• Screening: The Shield test, which is an FDA-approved blood test used to check adults aged 45 and older for signs of colorectal cancer.
• Monitoring and Research: Guardant Reveal detects leftover cancer cells after surgery, while GuardantINFORM provides a large database of genomic information to help drug companies study how tumors change over time.
• Biopharmaceutical Services: Testing and data analysis services provided to drug developers to assist in clinical trials and the creation of companion diagnostics, which are tests required to see if a specific drug will work for a patient.

New Frontiers and Partnerships

• Signed a partnership with Policlinico Gemelli in Italy in September 2024 to set up an in-house liquid biopsy testing service.
• Launched a partnership with Adicon Holdings Limited in China in December 2023 to provide genomic profiling for clinical research.
• Collaborated with The Royal Marsden NHS Foundation Trust in the UK to offer blood-based cancer testing starting in April 2023.
• Gained national reimbursement approval for the Guardant360 CDx test from Japan's Ministry of Health, Labour and Welfare in July 2023.

What Makes Guardant Different

The company uses its proprietary Smart Platform to look at multiple types of biological signals, including DNA and chemical changes called methylation, from a single blood draw. By building a massive database of genomic data through its GuardantINFORM platform, it helps drug companies identify why some cancers become resistant to treatment.

The Latest Numbers

• Revenue grew to $281 million in Q4 2025, representing a 39% increase compared to Q4 2024.
• Gross profit reached $182 million in Q4 2025, up 46% from the previous year.
• Free cash flow improved to negative $42 million in Q4 2025, up 50% from the $83 million loss reported in Q4 2024.
• Operating cash flow was negative $14 million in Q4 2025, a 78% improvement over the previous year's $65 million loss.

Bottom Line

Guardant has transitioned from a specialized testing laboratory into a broad oncology data company serving patients, doctors, and drug developers. Its expansion into early cancer screening and international partnerships supports its goal of managing cancer across every stage of the disease.